Upadacitinib in the management of Crohn's disease and novel data challenging standard clinical practice are some of the inflammatory bowel disease (IBD) highlights from Digestive Disease Week (DDW) 2023, as reported by Dr Joseph Feuerstein, from Harvard Medical School, Boston, Massachusetts.
Dr Feuerstein begins by discussing two studies of upadacitinib induction and maintenance in Crohn's disease. Both studies showed that the drug achieved higher fistula closure and remission rates than did placebo, regardless of prior biologic therapy exposure.
The third study chosen by Dr Feuerstein asks whether early resection of ileocecal Crohn's disease might achieve better outcomes than would standard anti–tumor necrosis factor therapy. The study results suggested that early resection could postpone the need for medication for longer than previously thought.
More potentially practice-changing data comes from the SuPREMe-CD study, which showed that using Kono-S anastomosis reduced endoscopic recurrence of Crohn's disease compared with traditional side-to-side anastomosis.
Dr Feuerstein next discusses an analysis of the SAPPHIRE Registry, which found that IBD treatments were not linked to cancer risk. In closing, he reports on a study that showed longer withdrawal time during colonoscopy, meaning longer time spent examining the colon, is associated with improved detection of polypoid dysplasia.
--
Joseph D. Feuerstein, MD, Associate Professor of Medicine, Department of Gastroenterology, Harvard Medical School; Attending in Gastroenterology, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Joseph D. Feuerstein, MD, has disclosed no relevant financial relationships.
Digestive Disease Week® was sponsored by the American Gastroenterological Association, the American Association for the Study of Liver Diseases, the American Society for Gastrointestinal Endoscopy, and the Society for Surgery of the Alimentary Tract.
